P/B
1
Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
$230.1M
Market Cap • 10/23/2026
2018
(8 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
8522,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
9,5
EPS
—
Market Cap
Market Cap
230,1M
EV
62,9M
EV/Revenue
2330,9
EV/EBITDA
-0,3
EV/EBIT
-0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-44,5%
Total Yield
-44,5%
Payout
0%
Retained Earnings
-1,7B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
825300%
Capex/Revenue
2633,3%
Capex/D&A
7,5%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
15,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-68,3%
CAGR Op. Income 5Y
5,7%
CAGR Net Income 5Y
5,3%
CAGR EPS 5Y
-41,7%
CAGR OCF 5Y
2,8%
Leverage
N.D./EBITDA
0,7
Debt/Equity
0%
Current Ratio
5,4
Quick Ratio
5,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!